Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Products under Development by Stage of Development | 7 | 1 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Products under Development by Therapy Area | 8 | 1 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Products under Development by Indication | 9 | 1 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Products under Development by Companies | 12 | 2 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Products under Development by Universities/Institutes | 14 | 2 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Therapeutics Assessment | 16 | 7 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Companies Involved in Therapeutics Development | 23 | 5 |
| Adverum Biotechnologies, Inc. | 23 | 1 |
| Bio Blast Pharma Ltd. | 24 | 1 |
| ProQR Therapeutics N.V. | 25 | 1 |
| RaNA Therapeutics, Inc. | 26 | 1 |
| Voyager Therapeutics, Inc. | 27 | 1 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Drug Profiles | 28 | 13 |
| AGIL-FA Drug Profile | 28 | 1 |
| ANN-003 Drug Profile | 29 | 2 |
| BB-FA Drug Profile | 31 | 1 |
| Gene Therapy to Activate Frataxin for Friedreich s Ataxia Drug Profile | 32 | 1 |
| Gene Therapy to Activate Frataxin for Friedreich s Ataxia Drug Profile | 33 | 1 |
| Gene Therapy to Activate Frataxin for Friedrich's Ataxia Drug Profile | 34 | 1 |
| JOT-101 Drug Profile | 35 | 1 |
| Oligonucleotide to Activate Frataxin for Friedreich's Ataxia Drug Profile | 36 | 1 |
| QRX-604 Drug Profile | 37 | 1 |
| Recombinant Protein for Friedreich Ataxia Drug Profile | 38 | 1 |
| TAT-FXN Drug Profile | 39 | 1 |
| VYFXN-01 Drug Profile | 40 | 1 |
| Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) Featured News &Press Releases | 41 | 3 |
| Aug 02, 2016: Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich s Ataxia | 41 | 1 |
| Aug 05, 2015: Key Patent Granted For AAVLife s Gene-Therapy Program to Treat Cardiomyopathy in Friedreich s Ataxia | 41 | 1 |
| Jun 18, 2015: BioBlast Pharma to Present Preclinical Proofs of Concept in Friedreich s Ataxia at Two Leading Scientific Meetings in June | 42 | 1 |
| Mar 26, 2015: BioBlast Pharma Announces Positive Preclinical Proof-of-Concept Results of Its Novel Mitochondrial Protein Replacement Platform in Friedreich's Ataxia | 43 | 1 |
| Dec 17, 2014: BioBlast Receives Notice of Patent Issuance From USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia | 43 | 1 |
| Appendix | 44 | 2 |
| Methodology | 44 | 1 |
| Coverage | 44 | 1 |
| Secondary Research | 44 | 1 |
| Primary Research | 44 | 1 |
| Expert Panel Validation | 44 | 1 |
| Contact Us | 44 | 1 |
| Disclaimer | 45 | 1 |
